Citadel Advisors
PMVP icon

Citadel Advisors’s PMV Pharmaceuticals PMVP Stock Holding History

Citadel Advisors’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100
Closed -$109 – 14507
2025
Q1 		$109 Sell
100
-400
-80% -$543 ﹤0.01% 14332
2024
Q4 		$755 Sell
500
-1,200
-71% -$1.9K ﹤0.01% 14275
2024
Q3 		$2.53K Buy
1,700
+1,600
+1,600% +$2.47K ﹤0.01% 13740
2024
Q2 		$162 Sell
100
-500
-83% -$902 ﹤0.01% 14081
2024
Q1 		$1.02K Sell
600
-5,200
-90% -$9.71K ﹤0.01% 14203
2023
Q4 		$18K Hold
5,800
– – ﹤0.01% 12709
2023
Q3 		$35.6K Buy
5,800
+2,500
+76% +$17.2K ﹤0.01% 12139
2023
Q2 		$20.7K Buy
3,300
+1,700
+106% +$8.91K ﹤0.01% 12701
2023
Q1 		$7.63K Buy
1,600
+500
+45% +$3.52K ﹤0.01% 13703
2022
Q4 		$9.57K Buy
+1,100
New +$11.7K ﹤0.01% 13669
2022
Q3 		– Sell
-16,900
Closed -$241K – 13363
2022
Q2 		$241K Sell
16,900
-118,800
-88% -$1.73M ﹤0.01% 10292
2022
Q1 		$2.83M Buy
+135,700
New +$2.39M ﹤0.01% 5327

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Citadel Advisors's PMVP Position: Q2 2026 in Review

Citadel Advisors increased its PMV Pharmaceuticals (PMVP) stake by 5% in Q2 2026, buying an estimated $2.9K and bringing the position to 47,308 shares worth $63.4K. The position accounts for ﹤0.01% of the portfolio, ranked #12996.

Citadel Advisors first reported a position in PMVP in Q3 2020 and has held it in 24 quarters since. The position peaked at $20.1M in Q2 2022. 64 funds tracked by Wall St. Rank hold PMVP as of Q2 2026.

  • Citadel Advisors held 47,308 shares of PMV Pharmaceuticals worth $63.4K as of Q2 2026.
  • Citadel Advisors bought 2,260 PMV Pharmaceuticals shares in Q2 2026, an estimated $2.9K.
  • PMV Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12996 holding.
  • Citadel Advisors first reported a position in PMV Pharmaceuticals in Q3 2020 and has held it in 24 quarters since.
  • Citadel Advisors's PMV Pharmaceuticals position peaked at $20.1M in Q2 2022.
  • 64 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.